Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Elranatamab”

56 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 56 results

Not applicableNot Yet RecruitingNCT07564128
What this trial is testing

Infection Surveillance of R/R Multiple Myeloma Patients Treated With Elranatamab as Clinical Practice in Italy

Who this might be right for
Multiple Mieloma
Gruppo Italiano Malattie EMatologiche dell'Adulto 50
Large-scale testing (Phase 3)Looking for participantsNCT06918002
What this trial is testing

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Intergroupe Francophone du Myelome 824
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06931704
What this trial is testing

Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

Who this might be right for
Multiple Myeloma
Nantes University Hospital 176
Testing effectiveness (Phase 2)Looking for participantsNCT06207799
What this trial is testing

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Who this might be right for
Multiple MyelomaPost-transplant MRD-guided Maintenance TherapyPre-transplant Purging
M.D. Anderson Cancer Center 40
Testing effectiveness (Phase 2)Looking for participantsNCT06832865
What this trial is testing

ELISA in Relapsed/Refractory MM

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)Relapsed Refractory Multiple Myeloma
Massachusetts General Hospital 30
Early research (Phase 1)Study completedNCT03269136
What this trial is testing

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 101
Testing effectiveness (Phase 2)Looking for participantsNCT06920251
What this trial is testing

Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Seoul National University Hospital 40
Early research (Phase 1)Study completedNCT04798586
What this trial is testing

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Pfizer 4
Early research (Phase 1)Looking for participantsNCT07280013
What this trial is testing

Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Who this might be right for
Multiple Myeloma (MM)
C4 Therapeutics, Inc. 60
Not applicableNot Yet RecruitingNCT07788469
What this trial is testing

Elranatamab for Inhibitor Eradication in Patients With Hemophilia A

Who this might be right for
Hemophilia A With Inhibitors
Institute of Hematology & Blood Diseases Hospital, China 20
Large-scale testing (Phase 3)Looking for participantsNCT06152575
What this trial is testing

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Who this might be right for
Multiple Myeloma
Pfizer 492
Testing effectiveness (Phase 2)Looking for participantsNCT06421675
What this trial is testing

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
Ontario Clinical Oncology Group (OCOG) 40
Not applicableStudy completedNCT06504524
What this trial is testing

Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Who this might be right for
Multiple Myeloma
Pfizer 633
Not applicableActive Not RecruitingNCT06479954
What this trial is testing

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Pfizer 1
Large-scale testing (Phase 3)Looking for participantsNCT05020236
What this trial is testing

Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Who this might be right for
Multiple Myeloma
Pfizer 893
Testing effectiveness (Phase 2)Looking for participantsNCT06988488
What this trial is testing

Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 62
Not applicableNo Longer AvailableNCT05462639
What this trial is testing

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer
Testing effectiveness (Phase 2)Looking for participantsNCT06711705
What this trial is testing

Elranatamab in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of California, San Diego 33
Testing effectiveness (Phase 2)Ended earlyNCT05090566
What this trial is testing

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 46
Large-scale testing (Phase 3)Not Yet RecruitingNCT07647432
What this trial is testing

HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

Who this might be right for
Plasmablastic LymphomaHivConsolidation
University of Illinois at Chicago 17
Next Page